Fusion protein of streptococcal pyrogenic exotoxins

Details Fusion protein of streptococcal pyrogenic exotoxins Fusion protein of streptococcal pyrogenic exotoxins

2006-08-08

2006-08-08

Minnifield, Nita (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100, C424S192100, C424S190100, C424S185100, C424S234100, C424S237100, C424S244100, C530S350000, C530S402000

Reexamination Certificate

active

07087235

ABSTRACT:
The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.

REFERENCES:
patent: 6338845 (2002-01-01), Terman
patent: 6340461 (2002-01-01), Terman
patent: 6399332 (2002-06-01), Ulrich et al.
patent: 6632441 (2003-10-01), Schlievert et al.
patent: 6632640 (2003-10-01), Lee et al.
patent: 6692746 (2004-02-01), Terman et al.
patent: 6713284 (2004-03-01), Ulrich et al.
patent: 6835818 (2004-12-01), Schlievert et al.
patent: 6870042 (2005-03-01), Schlievert et al.
patent: 6872394 (2005-03-01), Bohach
patent: 6913755 (2005-07-01), Schlievert et al.
patent: 2002/0054887 (2002-05-01), Schlievert et al.
patent: 2003/0009015 (2003-01-01), Ulrich et al.
patent: 2003/0092894 (2003-05-01), Antonsson et al.
patent: 2004/0009183 (2004-01-01), Lee et al.
patent: 2004/0236082 (2004-11-01), Marshall et al.
patent: 2005/0026272 (2005-02-01), Bohach
patent: 2005/0153376 (2005-07-01), Fraser et al.
patent: WO 94/22474 (1994-10-01), None
patent: WO 96/14744 (1996-05-01), None
patent: WO 96/40930 (1996-12-01), None
patent: WO 98/24911 (1998-06-01), None
patent: WO 00/09154 (2000-02-01), None
patent: WO 03/056015 (2003-07-01), None
Llewelyn et al, Critical Care 2001, 5:53-58.
Carra et al, Clinical Immunology, 2003, 108:60-68.
Roggiani et al, Infection and Immunity, Sep. 2000, 68/9:5011-5017.
Bavari et al, J. Cellular Biochemistry, 1995, Suppl. 21A, abstract.
Bavari et al, J. Infectious Diseases, 1996, 174:338-345.
Bavari et al, Vaccines 1996, 96:135-141.
Nelson et al, J. Exp. Med., Nov. 1991, 174:1271-1274.
Papageorgiou et al, EMBO Journal, 1999, 18/1:9-21.
Johnson et al, Mol. Gen. Genet., 1986, 203:354-356.
Weeks et al, Infection and Immunity, Apr. 1986, 52/1:144-150.
Smoot et al, PNAS, USA, Apr. 2002, 99/7:4668-4673.
Bessen et al, J. Infectious Diseases, 1999, 179:627-636.
International Search Report for PCT/US01/46540, pp. 1-3, mailed Nov. 21, 2002 (corresponding international application to 10/002,784).
Earhart et al., “Structures of Five Mutants of Toxic Shock Syndrome Toxin-1 with Reduced Biological Activity”, Biochemistry, vol. 37, 1998, pp. 7194-7202.
Hurley, et al., “Identification of class II major histocompatibility complex and T cell receptor binding sites in the superantigen toxic shock syndrome toxin 1”, J. Experimental Medicine, vo. 181, Jun. 1995, pp. 2229-2235.
Bavari et al., “Engineered Bacterial Superantigen Vaccines”, Vaccines, vol. 96, 1995, pp. 135-141.
Bavari et al., “Superantigen Vaccines: A Comparative Study of Genetically Attenuated Receptor-Binding Mutants of Staphylococcal Enterotoxin A”, J. Infectious diseases, vol. 174, No. 2, 1996, pp. 338-345.
Kappler et al., “VB-Specific Stimulation of Human TCells by Staphylococcal Toxins”, 1989, Science, vol. 244, pages 811-813.
Karlson, et al., “Kinetic analysis of monoclonal antibody-antigen interactions with a new blosensor based analytical system”, J. Immunological Methods, 145 (1991), pages 229-240.
Johnson et al., “Real-Time Biospecific Interaction Analysis Using Surface Plasmon Resonance nad a Sensor Chip Technology”, Biotechniques, vol. 11, No. 5, 1991, pages 620-627.
Prased et al., “Structure of Toxic Shock Syndrome Toxin 1”, Biochemistry, Accelerated Publications, vol. 32, No. 50, 1993, pages 13761-13766.
Acharya, et al., “Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1”, Nature, vol. 367, Jan. 6, 1994, pages 94-97.
Swaminathan et al., “Crystal structure of staphylococcal enterotoxin B, a superantigen”, Nature, vol. 359, Oct. 29, 1992, pages 801-806.
Ulrich et al., “Staphylococcal enterotoxins A and B share a common structural motif for binding class II major histocompatibility complex molecules”, Nature Structural Biology, vol. 2, No. 6, Jun. 1995, pages 554-560.
Kuo et al., “Role of Streptococcal Pyrogenic Exotoxin B in the Mouse Model of Group A Streptococcal Infection”, Infection and Immunity, Aug. 1998, vol. 66, No. 8, pages 3931-3935.
Kapur et al., “A conserved Streptococcus pyrogenes extracellular cysteine protease cleaves human fibronectin and degrades vitronectin”, Microbial Pathogenesis, 1993, vol. 15, pages 327-346.
Kapur et al., “Cleavage of interleukin 1B (1B-1B) precursor to produce active IL-1B by a conserved extracellular systeine protease from streptococcus pyogenes”, Proc. Natl. Acad. Sci, USA, vol. 90, Aug. 1993, pages 7676-7680.
Kagawa et al., “Crystal Structure of the zymogen form of the group A Streptococcus virulence factor SpeB: And intergrin-binding cysteine protease”, PNAS, Feb. 29, 2000, vol. 97, No. 5, pages 2235-2240.
Gubba et al., “Replacement of Histidine 340 with Alanine Inactivates the Group A Streptococcus Extracellular Cysteine Protease Viruslence Factor”, Infection and Immunity, Jun. 2000, vol. 68, No. 6, pages 3716-3719.
Stiles et al., “Toxicity of Staphyloccal Enterotoxins Potentiated by Lipopolysaccharide: Major Histocompatibility Complex Class II Moelcule Dependency and Cytokine Release”, Infection and Immunity, Dec. 1993, vol. 61, No. 12, pages 5333-5338.
Baker et al., “Structural features of a binding site in the superantigen streptococcal pyrogenic exotoxin A (SpeA1): Implications for MHC class II recognition,” Protein Sciences, 2001, vol. 10, pages 1268-1273.

Affiliated with

Also associated with

Rating

Fusion protein of streptococcal pyrogenic exotoxins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fusion protein of streptococcal pyrogenic exotoxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fusion protein of streptococcal pyrogenic exotoxins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3618505